^
    22h
    Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    1d
    ZGR: Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • cytarabine • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    1d
    ZGR in TN FL: Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=34, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    6d
    Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • Monjuvi (tafasitamab-cxix)
    6d
    MAGNAZ: Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, UMC Utrecht | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Mar 2029 | Trial primary completion date: Oct 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Brukinsa (zanubrutinib)
    6d
    SILVERGLO: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    7d
    Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. (PubMed, Blood Cancer J)
    Covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib are effective but alterations in the kinase domain at C481 or BTK gatekeeper residue T474 mutations result in development of resistance...We evaluated the efficacy of a new ncBTKi, docirbrutinib (AS-1763), against 14 BTK mutants, including C481S, T474x, and L528x, as well as gatekeeper and kinase domain double mutants, using biochemical assays, cell-line models, and primary CLL lymphocytes. Docirbrutinib potently inhibited BTK autophosphorylation and mutant BTK-driven cell proliferation, with greater effects than ibrutinib and pirtobrutinib against certain mutants. In treatment-naïve and relapsed/refractory CLL samples, docirbrutinib disrupted B-cell receptor signaling and sensitized cells to apoptosis induced by venetoclax and AZD5991. In a dose-escalation trial (NCT05602363), docirbrutinib decreased CCL3/CCL4 biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with relapsed/refractory CLL. These findings establish docirbrutinib as a pan-mutant ncBTKi with potential to improve outcomes for CLL patients, including those with disease resistant to cBTKi and other ncBTKi.
    Preclinical • Journal
    |
    CCL3 (C-C Motif Chemokine Ligand 3)
    |
    BTK C481S
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Jaypirca (pirtobrutinib) • AZD5991 • docirbrutinib (AS-1763)
    15d
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Recruiting, BeOne Medicines | N=186 --> 500
    Enrollment change • Trial initiation date
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Beqalzi (sonrotoclax)
    15d
    MAZINGA: Zanubritnib and Anti-MAG Neuropathy (clinicaltrials.gov)
    P2, N=50, Recruiting, Azienda Ospedaliera di Padova | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brukinsa (zanubrutinib)
    17d
    BGB-3111-2005-IIT: An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients (clinicaltrials.gov)
    P2, N=6, Terminated, Xuanwu Hospital, Beijing | N=20 --> 6 | Recruiting --> Terminated; Difficult in participant recruiting
    Enrollment change • Trial termination
    |
    Brukinsa (zanubrutinib)
    18d
    CaDAnCe-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=80, Recruiting, BeOne Medicines
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    18d
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia (2025-524366-21-00)
    P2/3, N=161, Not yet recruiting, BeOne Medicines I GmbH
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Beqalzi (sonrotoclax)